Advice for Community Oncologists Treating R/R Multiple Myeloma

Opinion
Video

Samer Al'Hadidi, MD, offers advice to community oncologists who treat patients with relapsed/refractory multiple myeloma, and the Oncology Brothers recap the entire discussion.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
      Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
      Frontline Setting of Pancreatic Cancer
      Frontline Setting of Pancreatic Cancer
      Treatment Algorithm for Metastatic Pancreatic Cancer
      Treatment Algorithm for Metastatic Pancreatic Cancer
      Role of Radiation in Pancreatic Cancer Treatment
      Role of Radiation in Pancreatic Cancer Treatment
      NGS and Germline Testing in Pancreatic Cancer
      NGS and Germline Testing in Pancreatic Cancer
      Overview of Pancreatic Cancer Treatment Approach
      Overview of Pancreatic Cancer Treatment Approach
      Deciding Which RP to Utilize
      Deciding Which RP to Utilize
      Making Sense of PARP Inhibitors
      Making Sense of PARP Inhibitors
      Consideration for Other Androgen Receptor Inhibitors
      Consideration for Other Androgen Receptor Inhibitors
      Prostate Cancer in 2025
      Prostate Cancer in 2025
      Related Content
      Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

      Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

      Tim Cortese
      June 19th 2025
      Article

      Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

      Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

      Ariana Pelosci
      June 16th 2025
      Article

      The MagnetisMM-6 trial results showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

      Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

      Russ Conroy
      June 16th 2025
      Article

      Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

      Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

      Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

      Ariana Pelosci
      June 14th 2025
      Article

      Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.